Description: <p><b>1,8-Cineole</b> — 1,8-cineole, also called eucalyptol, is a volatile bicyclic monoterpene ether and major active constituent of eucalyptus oil and several other aromatic plant oils (other plants such as oregano (Origanum spec.), thyme (Thymus spec.), guava (Psidium pohlianum) or sage (Salvia spec.)). Eucalyptus oil used for medicinal applications should contain at least 70% of 1,8-Cineol. It is best classified as a small-molecule phytochemical / essential-oil monoterpenoid rather than as a botanical extract. Its main established human-use identity is respiratory anti-inflammatory / mucolytic support, while its oncology relevance is preclinical and concentration-limited.</p>
<p><b>Primary mechanisms (ranked):</b></p>
<ol>
<li>Apoptosis induction through ↓ Akt / ↓ survivin with ↑ p38 MAPK, ↑ cleaved caspase-3, and ↑ cleaved PARP in colorectal cancer models.</li>
<li>Suppression of PI3K / Akt / mTOR signaling linked to reduced migration and invasion in skin cancer models.</li>
<li>Anti-proliferative and cell-cycle stress effects, including reduced BrdU incorporation and tumor-growth suppression in xenograft models.</li>
<li>Oxidative-stress-linked apoptosis or senescence in selected models; this appears model-dependent and may require high concentrations.</li>
<li>Anti-inflammatory cytokine suppression, including ↓ TNF-α and ↓ IL-1β, which is better established in inflammatory/airway contexts than as a direct cancer mechanism.</li>
<li>Membrane penetration / formulation effects, relevant to delivery and topical/transmucosal exposure but not a cancer-selective mechanism.</li>
</ol>
<p><b>Bioavailability / PK relevance:</b> 1,8-cineole is orally and inhalationally absorbed and undergoes rapid systemic distribution, with CYP3A-mediated oxidation as an important metabolic route. Enteric-coated oral preparations can deliver measurable tissue exposure in airway/nasal tissues, but oncology-relevant systemic concentrations are not established.</p>
<p><b>In-vitro vs systemic exposure relevance:</b> Many anticancer studies use millimolar-range in-vitro concentrations or concentrated essential-oil fractions, which likely exceed routine achievable systemic exposure from conventional oral or inhaled use. Direct cancer-cell effects should therefore be marked as exposure-constrained unless a delivery formulation is specified.</p>
<p><b>Clinical evidence status:</b> Preclinical oncology only. There is cell-line and animal/xenograft evidence for anticancer activity, but no established cancer-directed clinical efficacy. Human clinical deployment is mainly respiratory/supportive use of eucalyptus oil or purified 1,8-cineole preparations, not antineoplastic therapy.</p>
<h3>1,8-Cineole Cancer Mechanism Summary</h3>
<table>
<thead>
<tr>
<th>Rank</th>
<th>Pathway / Axis</th>
<th>Cancer Cells</th>
<th>Normal Cells</th>
<th>TSF</th>
<th>Primary Effect</th>
<th>Notes / Interpretation</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Akt / survivin / p38 apoptosis axis</td>
<td>↓ Akt; ↓ survivin; ↑ p38; ↑ cleaved PARP; ↑ caspase-3</td>
<td>Limited direct selectivity data</td>
<td>G</td>
<td>Apoptosis and tumor-growth suppression</td>
<td>Core anticancer mechanism in colorectal cancer models; likely high-concentration dependent.</td>
</tr>
<tr>
<td>2</td>
<td>PI3K / Akt / mTOR invasion axis</td>
<td>↓ PI3K; ↓ Akt; ↓ mTOR; ↓ migration; ↓ invasion</td>
<td>Not well established</td>
<td>G</td>
<td>Anti-invasive and anti-metastatic signaling</td>
<td>Mechanistically central in skin cancer models; therapeutic translation remains preclinical.</td>
</tr>
<tr>
<td>3</td>
<td>Cell proliferation and cell-cycle stress</td>
<td>↓ proliferation; ↓ BrdU incorporation; ↑ growth arrest (model-dependent)</td>
<td>Unclear</td>
<td>G</td>
<td>Cytostatic pressure and reduced tumor expansion</td>
<td>Observed across multiple cancer models, but dose ranges often exceed routine clinical exposure.</td>
</tr>
<tr>
<td>4</td>
<td>ROS-linked apoptosis or senescence</td>
<td>↑ ROS (model-dependent); ↑ oxidative stress-linked death or senescence</td>
<td>May show anti-inflammatory or antioxidant-context effects</td>
<td>G</td>
<td>Context-dependent oxidative stress leverage</td>
<td>Evidence is mixed by model and preparation; stronger when using 1,8-cineole-rich extracts or high concentrations.</td>
</tr>
<tr>
<td>5</td>
<td>Inflammatory cytokine signaling</td>
<td>Potential ↓ NF-κB-linked inflammatory support (context-dependent)</td>
<td>↓ TNF-α; ↓ IL-1β; ↓ airway inflammatory signaling</td>
<td>R/G</td>
<td>Anti-inflammatory modulation</td>
<td>Better supported for airway/inflammatory disease than for direct cancer-cell killing.</td>
</tr>
<tr>
<td>6</td>
<td>Membrane penetration and formulation effects</td>
<td>May alter uptake of co-administered compounds (context-dependent)</td>
<td>Potential irritation or barrier disruption at high topical exposure</td>
<td>R/G</td>
<td>Delivery modifier</td>
<td>Important for essential-oil and topical/transmucosal contexts; not inherently tumor-selective.</td>
</tr>
<tr>
<td>7</td>
<td>CYP3A metabolism and drug-interaction constraint</td>
<td>↔ direct anticancer effect</td>
<td>CYP3A-mediated oxidation; systemic clearance</td>
<td>R/G</td>
<td>PK limitation</td>
<td>Potential relevance for co-administered drugs, especially where CYP3A substrates or inhibitors are involved.</td>
</tr>
<tr>
<td>8</td>
<td>Clinical Translation Constraint</td>
<td>High in-vitro concentrations may not map to systemic dosing</td>
<td>GI irritation, CNS toxicity risk in overdose, pediatric laryngospasm/seizure precautions</td>
<td>G</td>
<td>Translation barrier</td>
<td>Oncology status preclinical; established human use is respiratory/supportive rather than antineoplastic.</td>
</tr>
</tbody>
</table>
<p>TSF legend: P: 0–30 min; R: 30 min–3 hr; G: >3 hr</p>